PREMARKET ALERT: Rigel Pharmaceuticals

Posted in General 
July 9th, 2009

Rigel Pharmaceuticals Inc. (RIGL) shares are up more than 30 percent to nearly $15 as of premarket trading of about 100,000 shares around 8:30 a.m. Eastern. The company said earlier this morning that R788 produced significant clinical improvement in rheumatoid arthritis patients in the trial. The company hopes to start a Phase III trial in the first half of 2010, with help from a partner. — Mike Tarsala

For full details, see BioHealthInvestor.com

Comments are closed

-->